ストックスクリーナーアプリを入手
20.80
0.91%
-0.19
アフターアワーズ：
20.70
-0.10
-0.48%
前日終値:
$20.99
開ける：
$20.7
24時間の取引高:
118.39K
Relative Volume:
0.47
時価総額：
$526.22M
収益：
-
当期純損益:
-
株価収益率:
-
EPS:
-
ネットキャッシュフロー:
-
1週間 パフォーマンス:
-6.56%
1か月 パフォーマンス:
-7.56%
6か月 パフォーマンス:
+0.00%
1年 パフォーマンス:
+0.00%
1日の値動き範囲:
$20.52
$21.10
1週間の範囲:
$19.38
$22.64
52週間の値動き範囲:
$13.36
$23.15
Lb Pharmaceuticals Inc Stock (LBRX) Company Profile
LBRX を他の銘柄と比較する
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
LBRX
Lb Pharmaceuticals Inc
|
20.80 | 531.03M | 0 | 0 | 0 | 0.00 |
|
VRTX
Vertex Pharmaceuticals Inc
|
469.68 | 122.84B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
801.01 | 85.37B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
399.40 | 55.82B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ARGX
Argen X Se Adr
|
795.57 | 50.67B | 3.06B | 1.28B | 447.35M | 19.67 |
|
INSM
Insmed Inc
|
170.27 | 37.54B | 447.02M | -1.18B | -906.14M | -6.1812 |
Lb Pharmaceuticals Inc Stock (LBRX) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2025-10-06 | 開始されました | Leerink Partners | Outperform |
| 2025-10-06 | 開始されました | Piper Sandler | Overweight |
| 2025-10-06 | 開始されました | Stifel | Buy |
Lb Pharmaceuticals Inc (LBRX) 最新ニュース
Poplar’s $50 million Series A to ‘transform treatment of atopic diseases’ - The Pharma Letter
LB Pharmaceuticals Appoints Ellen Rose and Lindsay Beaupre as Senior Vice Presidents - citybiz
LB Pharmaceuticals appoints two executives to leadership team By Investing.com - Investing.com Canada
LB Pharmaceuticals Strengthens Leadership Team with Key Appointments in Corporate Affairs and People & Culture - The Manila Times
Schizophrenia drug developer LB Pharma jumps in trading debut - MSN
LB Pharmaceuticals (NASDAQ:LBRX) Stock Price Down 7.7%Should You Sell? - MarketBeat
LB Pharmaceuticals (NASDAQ:LBRX) Trading Up 3.8%Here's Why - MarketBeat
Top financings 2025 - BioWorld MedTech
LB Pharmaceuticals Inc (NASDAQ:LBRX) Given Consensus Recommendation of "Moderate Buy" by Analysts - MarketBeat
LB Pharmaceuticals Inc(NasdaqGM: LBRX) added to S&P TMI Index - marketscreener.com
Aktis Oncology files for US IPO as biotech listings rebound - 1470 & 100.3 WMBD
Pai Panandiker Kaya Kamlesh Net Worth (2025) - GuruFocus
LB Pharmaceuticals Inc(NasdaqGM: LBRX) added to Russell 3000 Index - marketscreener.com
LB Pharmaceuticals Inc(NasdaqGM: LBRX) added to Russell 3000E Index - MarketScreener
LB Pharmaceuticals (NASDAQ:LBRX) Stock Price Up 5.6%What's Next? - MarketBeat
LB Pharmaceuticals Earnings Notes - Trefis
[Form 4] LB PHARMACEUTICALS INC Insider Trading Activity - Stock Titan
LB Pharmaceuticals added to Russell 2000 and 3000 Indexes - MSN
LB Pharmaceuticals (NASDAQ:LBRX) Stock Price Expected to Rise, Stifel Nicolaus Analyst Says - MarketBeat
Lexicon publishes preclinical data validating ACSL5 as obesity target By Investing.com - Investing.com Nigeria
LB Pharmaceuticals Reports Inducement Grant to New Employee Under Nasdaq Listing Rule 5635(c)(4) - The Manila Times
LB Pharmaceuticals (Nasdaq: LBRX) issues inducement equity grant to incoming CCO - Stock Titan
LB Pharmaceuticals (LBRX) Stock Analysis Report | Financials & Insights - Benzinga
Lexicon publishes preclinical data validating ACSL5 as obesity target - Investing.com
LB Pharmaceuticals Added to the Russell 2000 and Russell 3000 Indices - marketscreener.com
LB Pharmaceuticals (NASDAQ:LBRX) Trading Down 4.8%Here's Why - MarketBeat
LB Pharmaceuticals Added to Russell 2000, 3000 Indices - marketscreener.com
LB Pharmaceuticals to join Russell 2000 and Russell 3000 indices - Investing.com
LB Pharmaceuticals to join Russell 2000 and Russell 3000 indices By Investing.com - Investing.com Canada
LB Pharmaceuticals Added to the Russell 2000® and Russell 3000® Indices - marketscreener.com
LB Pharmaceuticals (NASDAQ:LBRX) Trading Up 6.2%Still a Buy? - MarketBeat
LB Pharmaceuticals (NASDAQ:LBRX) Hits New 52-Week HighHere's What Happened - MarketBeat
LBRX: $300M IPO funds phase III schizophrenia and phase II bipolar depression trials, with 2027 data expected - TradingView
LB Pharmaceuticals Inc (LBRX) Analyst Insights, Price Targets & Recommendations - Yahoo! Finance Canada
LB Pharmaceuticals Inc (NASDAQ:LBRX) Receives $30.50 Average PT from Brokerages - Defense World
LB Pharmaceuticals Inc (NASDAQ:LBRX) Receives Average Rating of "Buy" from Brokerages - MarketBeat
LB Pharmaceuticals Announces Presentation at the Piper Sandler 37th Annual Healthcare Conference - The Manila Times
Neuropsychiatric drug developer LB Pharma files for U.S. IPO - MSN
LB Pharmaceuticals Inc: Target Price Consensus and Analysts Recommendations | LBRX | US50180M1080 - MarketScreener
LB Pharmaceuticals Inc: Revenue and Earnings Analysts Forecasts Revisions | LBRX | US50180M1080 - MarketScreener
LB Pharmaceuticals Inc: Dividend historical data and projections - MarketScreener
Jazz Pharmaceuticals, Sigma Lithium, Zymeworks And Other Big Stocks Moving Higher On Monday - Benzinga
LB Pharmaceuticals Appoints New Chief Commercial Officer - MSN
LB Pharmaceuticals amends lease to expand New York office space By Investing.com - Investing.com Australia
LB Pharmaceuticals Expands Lease at One Penn Plaza - TipRanks
LB Pharmaceuticals amends lease to expand New York office space - Investing.com India
[8-K] LB PHARMACEUTICALS INC Reports Material Event | LBRX SEC FilingForm 8-K - Stock Titan
LB Pharmaceuticals appoints Kaya Pai Panandiker as chief commercial officer - Investing.com Nigeria
Lb Pharmaceuticals Inc (LBRX) 財務データ
Lb Pharmaceuticals Inc (LBRX) の財務データはありません。詳細については、他の銘柄を確認してください。
収益
当期純利益
現金流量
EPS
0.80%
4.56%
大文字化:
|
ボリューム (24 時間):